rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
2000-12-20
|
pubmed:abstractText |
Daunomycin is a potent inducer of p53 and NF-kappaB transcription factors. It is also able to increase the amount of the p21 cyclin-dependent kinase inhibitor. The human p21 promoter harbors p53-responsive elements and an NF-kappaB binding site. We demonstrated, in human breast and colon carcinoma cells, the binding of NF-kappaB dimers to the kappaB site and the transcriptional activation of the human p21 promoter by daunomycin and by NF-kappaB subunits, thereby confirming the functionality of this kappaB binding site. However, using different tumor cell lines where p53 or NF-kappaB was inactive, we showed that p21 activation and cell cycle arrest induced by daunomycin was p53-dependent and NF-kappaB-independent, whereas daunomycin-induced apoptosis was p53- and NF-kappaB-independent.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0022-3565
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
295
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
870-8
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:11082419-Antibiotics, Antineoplastic,
pubmed-meshheading:11082419-Apoptosis,
pubmed-meshheading:11082419-Cell Cycle,
pubmed-meshheading:11082419-Cyclin-Dependent Kinase Inhibitor p21,
pubmed-meshheading:11082419-Cyclins,
pubmed-meshheading:11082419-DNA Damage,
pubmed-meshheading:11082419-Daunorubicin,
pubmed-meshheading:11082419-Gene Expression Regulation,
pubmed-meshheading:11082419-Humans,
pubmed-meshheading:11082419-NF-kappa B,
pubmed-meshheading:11082419-Promoter Regions, Genetic,
pubmed-meshheading:11082419-Tumor Cells, Cultured,
pubmed-meshheading:11082419-Tumor Suppressor Protein p53
|
pubmed:year |
2000
|
pubmed:articleTitle |
Roles of nuclear factor-kappaB, p53, and p21/WAF1 in daunomycin-induced cell cycle arrest and apoptosis.
|
pubmed:affiliation |
Laboratory of Medical Chemistry and Medical Oncology, University of Liège, Sart-Tilman, Liège, Belgium.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|